title: The clinical utility of precision medicine: properly assessing the value of emerging diagnostic tests.
abstract: Assessments of the clinical utility of biomarkers and genomic tests often ignore individual utility and fail to account for downstream changes to the care delivery model. Tests that identify outliers are often undervalued in favor of those that help direct treatment for the "average" patient. By reducing uncertainty, these tests also enable lower-cost providers and even patients to assume increased responsibility for care in more convenient and affordable settings.
authors.affiliation: School of Medicine, University of Iowa, Iowa City, Iowa, USA.
authors.forename: B
authors.initials: B
authors.lastname: Shen
authors.forename: J
authors.initials: J
authors.lastname: Hwang
mesh_terms: D003362:Cost-Benefit Analysis / Q000191:economics; D057069:Diagnostic Test Approval / Q000191:economics / Q000639:trends; D003955:Diagnostic Tests, Routine / Q000191:economics / Q000639:trends*; D006801:Humans; D057285:Precision Medicine / Q000191:economics / Q000639:trends*